ctDNA Predicts Relapse in Locally Advanced Cervical Cancer

Published Date: 17 Apr 2026

Posttreatment ctDNA positivity correlates with worse relapse-free survival and earlier recurrence in patients with locally advanced cervical cancer, real-world data show.

Read Full News

Latest News

Annual Cancer Report Highlights Advances, Funding Threats

A yearly report from the American Association for Cancer Research lauds recent breakthroughs but warns on threatened federal funding changes.

Does Telenursing Improve QOL in Breast Cancer?

A meta-analysis assesses the effect of nurse-led telenursing on the quality of life in women with breast cancer.

Long-Term Results Favor Acalabrutinib Combo in MCL

The 50-month follow-up of the ECHO trial underscores greater benefits with concurrent vs sequential addition of acalabrutinib to bendamustine and rituximab.

First-Line Combo Therapies Best Chemo Alone in NSCLC Trials

New phase 3 data add to a growing number of EGFR-directed first-line options for advanced NSCLC with EGFR exon 20 insertions.

3D Mammography Improves Long-Term Cancer Risk Prediction

Researchers develop and validate a deep learning model using longitudinal 3D tomosynthesis examinations to predict individualized 5-year risk for breast cancer.

Osimertinib's OS Benefit in Resected NSCLC Persists 8 Years

Even years after treatment ends, adjuvant osimertinib brings an overall survival benefit to patients with resected EGFR-mutated lung cancer.

Todays Updates

Optimizing Care Transitions and Referral Decision-Making Across the HNSCC Continuum

Optimizing Care Transitions and Referral Decision-Making Across the HNSCC Continuum

Liver Failure or Liver Mets?

Diagnosis complicated by absence of radiologic evidence of hepatic lesions

Here's Why Hematuria in a Young Patient Should Always Be Investigated

Terminology also makes a difference

Todays Updates

Optimizing Care Transitions and Referral Decision-Making Across the HNSCC Continuum

Optimizing Care Transitions and Referral Decision-Making Across the HNSCC Continuum

Liver Failure or Liver Mets?

Diagnosis complicated by absence of radiologic evidence of hepatic lesions

Here's Why Hematuria in a Young Patient Should Always Be Investigated

Terminology also makes a difference

Latest News

A yearly report from the American Association for Cancer Research lauds recent breakthroughs but warns on threatened federal funding changes.

A meta-analysis assesses the effect of nurse-led telenursing on the quality of life in women with breast cancer.

The 50-month follow-up of the ECHO trial underscores greater benefits with concurrent vs sequential addition of acalabrutinib to bendamustine and rituximab.

New phase 3 data add to a growing number of EGFR-directed first-line options for advanced NSCLC with EGFR exon 20 insertions.

Researchers develop and validate a deep learning model using longitudinal 3D tomosynthesis examinations to predict individualized 5-year risk for breast cancer.

Even years after treatment ends, adjuvant osimertinib brings an overall survival benefit to patients with resected EGFR-mutated lung cancer.

News All Time

Tissue-Free ctDNA Predicts Recurrence in Early Breast Cancer

Researchers analyzed plasma samples collected from 313 patients with early breast cancer approximately 2 years after they had completed adjuvant chemotherapy.

SBRT Plus Atezolizumab Shows No Benefit in Inoperable NSCLC

For patients with early-stage, inoperable lung cancer, adding atezolizumab to standard radiotherapy boosts toxicity, not survival.

TKI Discontinuation Feasible After ALL Treatment

In patients with first- or second-line Philadelphia-positive B-cell acute lymphoblastic leukemia, favorable outcomes are observed with discontinuation of ponatinib.

Sevabertinib Approved for First-Line Mutated NSCLC

The oral HER2 TKI was previously given accelerated approval in the second line for the indication.

A New PARADIGM? Azacitidine-Venetoclax Tops Chemo in AML

The less-intensive drug combination outperforms standard induction chemotherapy in fit patients with acute myeloid leukemia.

FDA Approves Camizestrant for ESR1-Mutated Breast Cancer

The accelerated approval enables an endocrine therapy switch when the ESR1 resistance mutation is detected, rather than waiting for evidence of disease progression.

Talc Powder Not Linked to Lung Cancer in Women

A study of US women finds no connection between talc powder use and lung cancer, though subgroup findings leave questions open.

Saturated Fat Tied to Worse Survival After Prostate Cancer

The association is driven by higher rates of death from cardiovascular disease and other cancers over 13 years.

Medication Self-Injection Embraced by Breast Cancer Patients

Women with breast cancer show interest in self-injecting their medication.

Can 80 Gy Radiation Boost Survival in Prostate Cancer?

A modest increase in radiation dose improves progression-free survival over 10 years among men with high-risk prostate cancer — but the overall survival benefits found in a French trial are uncertain.

Low Awareness of How to Spot Rare Breast Cancer Identified

Researchers survey US adults to assess their knowledge of inflammatory breast cancer.

Remote CBT for Insomnia Improves Symptoms During Chemo

A new randomized trial strengthens the case for managing cancer-related insomnia with cognitive-behavioral therapy.

Long-Acting Interferon Therapy Approved for ET

Ropeginterferon alfa-2b is designed to provide durable disease control.

Thymus Radiation Exposure Tied to Worse Lung Cancer Outcomes

The thymus is not routinely considered during thoracic radiotherapy planning, but new findings suggest that may need to change.

FDA Approves Rusfertide for Polycythemia Vera

Adding rusfertide to standard-of-care treatment cut phlebotomy rates by more than half in the phase 3 VERIFY trial.

Black Canadians Face Multiple Barriers to Blood Donation

Barriers to blood donations from Black people in Canada are rooted in racism and restrictive policies.

Recommended News For You

Interleukin-6 may boost prediction of obesity-related cancers

Risk of a Second Primary Melanoma Similar Regardless of Race/Ethnicity

Many patients learn they could have cancer in the emergency department

Prostate cancer explained: From antigen tests to treatment options

Experts Debate AQUILA Trial Findings in Smoldering Multiple Myeloma

AI is equally capable of reading breast cancer scans as human radiologists.

New First-Line Option for Advanced ALK-Positive Lung Cancer

Recommended Articles For You

AI Prediction of Hematologic Treatment Response 

Practical Concepts in Hematology and Patient Outcomes 

Driving Impact: Oncology Pharmaceutical Marketing Strategies in the USA 

Comprehensive Applications in Hematology for Better Care 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Adjuvant ICIs: A Winner and a Loser in Clear Cell Renal Cell Carcinoma?

2.

ctDNA Predicts Relapse in Locally Advanced Cervical Cancer

3.

In cancer survivors, loneliness is associated with a higher risk of death.

4.

Researchers discover cellular 'doorway' exploited by cancer-causing virus

5.

Pomalidomide Reduces Severe Epistaxis in Hereditary Bleeding Disease.

1.

Innovative Advances in Oncology for Specialists

2.

Understanding Bone Metastases: How Long Can Someone Live When Cancer Spreads To The Bones?

3.

Pediatric Oncology at the Cutting Edge: From Early Diagnosis to Lifesaving Therapies

4.

Understanding Protein C Deficiency: Symptoms, Causes, and Treatment

5.

Transfusing the Future: Exploring the Possibilities of Blood Transfusions

1.

International Cancer Conference

2.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

3.

International Cancer Conference

4.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part V

2.

Understanding the Difference Between Iron Deficiency and Other Types of Anemia

3.

Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)

4.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VIII

5.

Dacomitinib Case Presentation: Baseline Treatment and Current Status

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot